Provided by Tiger Trade Technology Pte. Ltd.

Neurosense Therapeutics Ltd

0.3472
+0.01524.58%
Post-market: 0.3399-0.0073-2.10%19:49 EDT
Volume:233.42K
Turnover:78.11K
Market Cap:13.11M
PE:-0.80
High:0.3491
Open:0.3450
Low:0.3300
Close:0.3320
52wk High:1.33
52wk Low:0.2500
Shares:37.77M
Float Shares:25.85M
Volume Ratio:0.18
T/O Rate:0.90%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4366
EPS(LYR):-0.4366
ROE:-2174.98%
ROA:-247.30%
PB:-8.41
PE(LYR):-0.80

Loading ...

Neurosense Therapeutics Ltd trading halted, news pending

TIPRANKS
·
15 hours ago

NASDAQ Trade Halt Halt News Pending at 07:50 Pm

Reuters
·
15 hours ago

NeuroSense Therapeutics to Present at H.C. Wainwright Global Investment Conference

Reuters
·
Sep 10

Neurosense Therapeutics Ltd: to Effect Reverse Share Split of Co’s Ordinary Shares at Ratio of 1-for-20

THOMSON REUTERS
·
Sep 10

NeuroSense Therapeutics Effects 1-for-20 Reverse Stock Split on Sept. 14, 2026

Reuters
·
Sep 10

NeuroSense Therapeutics Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
Sep 03

Neurosense Therapeutics Ltd. : H.c. Wainwright Initiates Coverage with Buy Rating and Target Price $8

THOMSON REUTERS
·
Sep 03

NeuroSense announces redesigned development plan for PrimeC

TIPRANKS
·
Aug 31

NeuroSense Targets Faster, Lower-Cost ALS Approval Path for PrimeC Under Revamped Development Plan

Reuters
·
Aug 31

NeuroSense Plans Head-to-Head PrimeC Trial Versus Mitsubishi Tanabe’s Edaravone in ALS

Reuters
·
Aug 31

Neurosense Unveils Accelerated, Capital-Efficient Strategy to Advance Primec Toward Potential Approval in ALS

THOMSON REUTERS
·
Aug 31

NeuroSense Therapeutics Shareholders Authorized Board to Pursue Reverse Stock Split Range 1-for-4 to 1-for-40

Reuters
·
Aug 28

NeuroSense Announces Shareholder Letter Availability

Reuters
·
Aug 13

NeuroSense Targets December 2026 Canada Filing for PrimeC ALS Drug Amid Phase 3 Paragon Preparations

Reuters
·
Aug 13

Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN) and Brookdale Senior Living (BKD)

TIPRANKS
·
Aug 11

NeuroSense sees December 2026 as filing date for NDS for PrimeC

TIPRANKS
·
Aug 06

NeuroSense Therapeutics Announces Special Shareholder Meeting

Reuters
·
Aug 01

NeuroSense Amends JonesTrading Equity Distribution Agreement for up to $3.79 Million Share Sales

Reuters
·
Aug 01

Neurosense Therapeutics Ltd Expected to Post Breakeven Results a Share - Earnings Preview

Reuters
·
Jul 28

Neurosense Therapeutics - Expects to File Submission to Health Canada in Coming Months

THOMSON REUTERS
·
Jul 22